Free Trial

Haemonetics (HAE) 10K Form and Latest SEC Filings 2026

Haemonetics logo
$66.12 +0.63 (+0.96%)
As of 11:52 AM Eastern

Latest Haemonetics SEC Filings & Recent Activity

Haemonetics (NYSE:HAE) has submitted 486+ documents to the U.S. Securities and Exchange Commission (SEC) since 2018. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Haemonetics's financial statements. The most recent filing was a Form 10-K submitted on May 20, 2026.

Form 4
HAEMONETICS CORP Reports Ownership Change on May. 19, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Haemonetics Files Current Report on May. 7, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-K
Haemonetics Files Annual Report on May. 20, 2026

The 10-K contains Haemonetics's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

Haemonetics SEC Filing History

Browse Haemonetics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/20/2026 5:31 AM
Haemonetics (313143) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
05/19/2026 4:37 PM
Basil Michelle L (1699629) Reporting
Haemonetics (313143) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/19/2026 4:28 PM
Haemonetics (313143) Issuer
Simon, Christopher (1674993) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/19/2026 4:29 PM
Haemonetics (313143) Issuer
Miller Laurie A. (1881751) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/19/2026 4:31 PM
Galvin Roy (1950021) Reporting
Haemonetics (313143) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/19/2026 4:33 PM
Haemonetics (313143) Issuer
Maunsell Farris Maryanne (1950052) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/19/2026 4:34 PM
DArecca James (1583903) Reporting
Haemonetics (313143) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/19/2026 4:36 PM
Chan Frank (2061743) Reporting
Haemonetics (313143) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/13/2026 9:40 AM
Haemonetics (313143) Subject
North Peak Capital Management, LLC (1747888) Filed by
Form SCHEDULE 13G/A
05/07/2026 5:02 AM
Haemonetics (313143) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/01/2026 3:18 PM
Haemonetics (313143) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/30/2026 9:29 AM
Haemonetics (313143) Subject
VANGUARD CAPITAL MANAGEMENT LLC (2100119) Filed by
Form SCHEDULE 13G
04/29/2026 12:38 PM
Haemonetics (313143) Subject
VANGUARD PORTFOLIO MANAGEMENT LLC (2100121) Filed by
Form SCHEDULE 13G
03/27/2026 8:33 AM
Haemonetics (313143) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
03/03/2026 5:24 PM
Haemonetics (313143) Subject
North Peak Capital Management, LLC (1747888) Filed by
Form SCHEDULE 13G
03/03/2026 5:09 AM
Haemonetics (313143) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/13/2026 9:10 AM
AQR CAPITAL MANAGEMENT LLC (1167557) Filed by
Haemonetics (313143) Subject
Form SCHEDULE 13G
02/05/2026 5:03 AM
Haemonetics (313143) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/05/2026 5:05 AM
Haemonetics (313143) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
01/09/2026 5:17 AM
Haemonetics (313143) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/06/2025 5:01 AM
Haemonetics (313143) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/06/2025 5:03 AM
Haemonetics (313143) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/03/2025 3:19 PM
Galvin Roy (1950021) Reporting
Haemonetics (313143) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/24/2025 3:20 PM
Haemonetics (313143) Issuer
Miller Laurie A. (1881751) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/12/2025 9:34 AM
Haemonetics (313143) Subject
WELLINGTON MANAGEMENT GROUP LLP (902219) Filed by
Form SCHEDULE 13G/A
08/07/2025 5:04 AM
Haemonetics (313143) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/07/2025 5:08 AM
Haemonetics (313143) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
07/25/2025 3:20 PM
Bryant Diane M (1687544) Reporting
Haemonetics (313143) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/25/2025 3:23 PM
COYLE MICHAEL J (1233311) Reporting
Haemonetics (313143) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/25/2025 3:25 PM
Dockendorff Charles J (1400563) Reporting
Haemonetics (313143) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/25/2025 3:28 PM
Haemonetics (313143) Issuer
Johnson Lloyd Emerson (1708823) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/25/2025 3:30 PM
Haemonetics (313143) Issuer
KROLL MARK W (1259254) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/25/2025 3:33 PM
Haemonetics (313143) Issuer
Pomeroy Claire (1603648) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/25/2025 3:36 PM
Haemonetics (313143) Issuer
Zane Ellen M (1369850) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/26/2025 9:49 AM
Haemonetics (313143) Subject
Llorens Josep (1750812) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/13/2025 3:21 PM
Galvin Roy (1950021) Reporting
Haemonetics (313143) Issuer
Form 4/A
06/12/2025 3:51 PM
Haemonetics (313143) Subject
Strong Stewart W (1420910) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/09/2025 3:49 PM
Haemonetics (313143) Issuer
Maunsell Farris Maryanne (1950052) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/06/2025 3:17 PM
Haemonetics (313143) Filer
Form DEF 14A
06/06/2025 3:18 PM
Haemonetics (313143) Filer
Form DEFA14A
06/04/2025 9:06 AM
Haemonetics (313143) Subject
Strong Stewart W (1420910) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
The SpaceX supplier that shipped 5 billion chips to Starlink (Ad)

When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, supplier Broadcom gained 15,000%. The pattern is clear: suppliers often dwarf the headline stock. One little-known company has shipped over 5 billion chips to SpaceX - a figure expected to reach 10 billion by 2027. SpaceX calls them 'instrumental to Starlink's success.' With the IPO expected in June, you can get the name, ticker, and a full year of tech research for just $19 - 85% off.tc pixel

Get the name and ticker before the SpaceX IPO arrives
06/03/2025 3:41 PM
Haemonetics (313143) Issuer
Simon, Christopher (1674993) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2025 3:31 PM
Basil Michelle L (1699629) Reporting
Haemonetics (313143) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/02/2025 12:16 PM
Haemonetics (313143) Subject
Strong Stewart W (1420910) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/27/2025 3:21 PM
Haemonetics (313143) Filer
Form SD
Specialized Disclosure Report  
(Data available from 1/1/2016 forward)

Haemonetics SEC Filings - Frequently Asked Questions

Haemonetics (HAE) has submitted 486+ filings to the SEC since 2018. You can browse the complete history or filter by form type using the tools above.

Haemonetics's fiscal year ends on March 31. The company typically files its 10-K annual report by the end of May, covering the prior fiscal year's financial results. Key financial data from these reports is available on Haemonetics's financial statements page.

The most recent filing was a Form 10-K submitted on May 20, 2026. This was the company's annual report for fiscal year 2025.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NYSE:HAE) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners